Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms

Tariq I. Mughal, Thomas Lion, Omar Abdel-Wahab, Ruben Mesa, Robyn M. Scherber, Danilo Perrotti, Michael Mauro, Srdan Verstovsek, Giuseppe Saglio, Richard A. Van Etten, Robert Kralovics

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Following the 47th American Society of Hematology Meeting in 2005, the late John Goldman and Tariq Mughal commenced a conference, the 1st Post-ASH Workshop, which brought together clinicians and scientists, to accelerate the adoption of new therapies for patients with myeloproliferative neoplasms (MPNs). The concept began with recognition of the CML success story following imatinib therapy, the discovery of JAK2V617F, and the demonstration that BCR-ABL1-negative MPNs are driven by abnormal JAK2 activation. This review is based on the presentations and deliberations at the XIIth Post-ASH Workshop on BCR-ABL1 positive and negative MPNs that took place on December 12 to 13, 2017, in Atlanta, Georgia, immediately following the 59th American Society of Hematology Meeting. We have selected some of the translational research and clinical topics, rather than an account of the proceedings. We discuss the role of immunotherapy in MPNs and the impact of the mutational landscape on TKI treatment in CML. We also consider how we might reduce TKI cardiovascular side effects, the potential role of nutrition as adjunctive nonpharmacologic intervention to reduce chronic inflammation in MPNs, and novel investigational therapies for MPNs.

Original languageEnglish (US)
Pages (from-to)740-748
Number of pages9
JournalHematological Oncology
Volume36
Issue number5
DOIs
StatePublished - Dec 2018
Externally publishedYes

Keywords

  • Chronic myeloroliferative neoplasms
  • genomics
  • immunotherapy
  • treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms'. Together they form a unique fingerprint.

Cite this